

Proj. Ref. No.:
End-User:
Project Name:

BAC4-21-033-A
Property and Supply Division
SUPPLY & DELIVERY OF VARIOUS DRUGS AND MEDICINES (AMPULES/VIALS) FOR CY 2022
(FRAMEWORK AGREEMENT) - REBID

ITEM NO.	QTY	UNIT	ITEM DESCRIPTION	ABC PER UNIT (PHP)	QUOTATIONS (all taxes included)	
					in figures	in words
2	16,750	piece	Atropine sulfate 1mg/mL, 1 mL ampul (IM, IV, SC)	26.50		
4	504	piece	Beractant 25 mg/ml suspension, 8mL Intratracheal administration vial	19,572.92		
5	204	piece	Beractant 25 mg/mL suspension, 4 mL Intratracheal administration vial	11,070.25		
11	2,660	piece	Deferoxamine mesilate powder, 500 mg vial (IM, IV infusion, SC)	343.95		
14	2,558	piece	Enoxaparin sodium 100mg/mL, 0.2mL pre-filled syringe (SC)	422.60		
15	6,000	piece	Ephedrine sulfate 50 mg/mL, 1 mL ampul (IM, IV) (With PDEA Permit)	91.50		
19	4,320	piece	Fluorescein (as sodium salt) 10% (100mg/mL), 5 mL ampul (IV)	575.00		
20	130	piece	Fondaparinux sodium 2.5 mg/0.5 mL solution (IV, SC)	1,389.15		
21	52	piece	Ganciclovir sodium 500 mg vial (IV infusion)	1,826.47		
22	15	piece	Goserelin acetate 10.8mg depot solution pre-filled syringe (SC)	14,077.89		
23	15	piece	Goserelin acetate 3.6mg depot solution, pre-filled syringe (SC)	4,118.80		
24	70	piece	Human recombinant tissue type plasminogen activator (alteplase) 50 mg powder for I.V. infusion	30,536.02		
28	1,770	piece	Isosorbide dinitrate 1mg/ml, 10mL ampule (IV)	792.00		
31	3,200	piece	Levetiracetam 500 mg/5 mL (100 mg/mL) concentrate solution for IV infusion, 5 mL vial	2,348.00		
32	4,810	piece	Levobupivacaine 5 mg/mL solution for injection, 10 mL ampule (Epidural/local infiltration)	210.00		
35	1,805	piece	Lidocaine Hydrochloride 2%, 1.8 mL carpule (with epinephrine) (local infiltration)	29.00		
36	440	piece	Linezolid 2 mg/mL (600 mg/300 mL), solution for infusion (IV)	3,820.00		
39	210	piece	Methotrexate sodium 100mg/mL, 10mL vial (IM, IV, Intrathecal) (preservative free)	7,500.00		
40	1,250	piece	Methylprednisolone 40 mg in single dose vial, solution for injection (IV, IM) (as sodium succinate)	668.90		
41	2,989	piece	Methylprednisolone lyophilized powder, 500 mg vial (IM, IV) (as sodium succinate)	1,256.00		

Approved by:

Dean VICENTE Y. BELIZARIO, JR., MD, MTM&H
Chairperson

(Signature over Printed Name of President/Gen. Manager)

(Name & Address of Company)

Proj. Ref. No.: BAC4-21-033-A
End-User: Property and Supply Division
Project Name: SUPPLY & DELIVERY OF VARIOUS DRUGS AND MEDICINES (AMPULES/VIALS) FOR CY 2022 (FRAMEWORK AGREEMENT) - REBID

ITEM NO.	QTY	UNIT	ITEM DESCRIPTION	ABC PER UNIT (PHP)	QUOTATIONS (all taxes included)	
					in figures	in words
43	9,050	piece	Morphine Sulfate 10 mg/mL, 1 mL ampul (IM, IV, SC) or 16 mg/mL, 1 mL ampul (IM, IV) (With PDEA Permit)	79.50		
45	2,435	piece	Naloxone hydrochloride 400 micrograms/mL, 1 mL ampul (IM, IV, SC)	338.04		
58	1,800	piece	Remifentanyl 1mg lyophilized powder vial (IV Infusion) (With PDEA Permit)	1,500.00		
61	5,104	piece	Sodium bicarbonate 1mEq/mL, 50mL ampul/vial (adult) (IV infusion)	119.99		
62	1,110	piece	Sodium Bicarbonate 1 mEq/mL, 100 mL ampul/vial (adult) (IV infusion)	275.32		
64	125	piece	Somatostatin 250mcg ampule/vial (IV, IV infusion)	798.00		
66	130	piece	Streptomycin sulfate 1 g vial (IM)	26.50		
67	112	piece	Valproic Acid 500 mg/ 5mL IV infusion, 5 mL vial	1,927.06		
69	2,510	piece	Vincristine sulfate 1 mg/mL, 1 mL vial (IV)	293.00		
70	2,540	piece	Vincristine sulfate 1 mg/mL, 2 mL vial (IV)	440.00		
72	330	piece	Voriconazole 200mg lyophilized powder for solution for IV infusion, 30mLVial	5,600.00		
TOTAL APPROVED BUDGET FOR THE CONTRACT: PhP47,286,599.45						

TERMS & CONDITIONS FOR THE SUPPLY & DELIVERY OF VARIOUS DRUGS AND MEDICINES (AMPULES/VIALS) FOR CY 2022 (FRAMEWORK AGREEMENT) - REBID

1

Indicate the **brand and packing of the item/s** offered.

2

The brand offered must be **at least five (5) years commercially available in the market from date of opening of bids.** Proof of this shall be the initial Certificate of Product Registration (CPR) issued by the Food and Drug Administration (FDA).

3

Submit the following documents, submission should be per product, with tab and per item number. Two (2) copies for the Valid Certificate of Product Registration and Certificate of Analysis (COA).

a.

Memorandum of Agreement (MOA) and Certificate of exclusive/authorized distributorship between the manufacturer and distributor. Distributors/suppliers must have certification from their principals that they are the exclusive distributor of the drug products authorized to submit tender for the product on behalf of the principal and that all commitments made by them shall be honored by the principal in case of termination of distributorship agreement.

b.

Valid Certificate of Product Registration (CPR) issued by the Food and Drug Administration (FDA).
- The name of the respective distributor should appear on the submitted CPR of the drug.
Note: CPRs that will expire within three (3) months from the date of opening of bids should present the Official Receipt of renewal of application with the Document Tracking log for the CPR from the FDA.

Approved by:

Dean VICENTE Y. BELIZARIO, JR., MD, MTM&H
Chairperson

(Signature over Printed Name of President/Gen. Manager)

(Name & Address of Company)

Proj. Ref. No.: BAC4-21-033-A
End-User: Property and Supply Division
Project Name: **SUPPLY & DELIVERY OF VARIOUS DRUGS AND MEDICINES (AMPULES/VIALS) FOR CY 2022 (FRAMEWORK AGREEMENT) - REBID**

- c. **Certificate of Analysis (COA)** for the products offered (batch to be delivered if awarded) duly issued by an FDA accredited laboratory (local) and should contain information indicated in monograph of the drug. Sample analyzed must not be expired during the time of bidding. The result of assay submitted must be in the specific brand and should be in the exact dosage formulation of the drug being bid. In cases where local laboratories are unavailable to perform drug assays, assays done abroad is accepted. The local COA is preferred and given more weight in the evaluation and awarding process.
- d. **A notarized certificate** that it is the innovator drug (if applicable).
- e. **Certificate of Good Manufacturing Process (CGMP).**
- f. **Valid License to Operate (LTO).**
- g. **A notarized certificate that the offered brand has not been subject to product complaint/product recall** for the past three (3) years.
- h. **Certificate of Acceptance** from at least three (3) major hospitals issued within the year and should be supported with Sales Invoice *(for new item/brand offered only)*.
- i. **A notarized certificate** that there are sufficient stocks for the offered item/s for one (1) year.
- 4 The offered drug must conform to the latest Philippine Food and Drug Administration (FDA) Administrative Order **governing the generic labeling and packaging requirements.**
 - 4.1 **For all tablets and capsules**
 - 4.1.1 **All tablets/capsules should be in foil or blister pack. A picture of the blister pack (front and back) should be submitted.**
 - 4.1.2 Each individual flap in the tablet or capsule blister pack should be labeled with the generic name and brand.
 - 4.1.3 Dosage form and strength of the Active Pharmaceutical Ingredients (API) should appear on each unit or every 2 units for products with multiple APIs.
 - 4.1.4 Name of drug, lot or batch number and expiry date must appear on every standard blister pack/foil strip and on the container or inner packing. However, if the product is not restricted for dispensing in quantities less than the standard blister pack or foil strip, the batch or lot number and expiry date should appear on each unit.
 - 4.1.5 Inner label must be the same as the outer label.
 - 4.1.6 A complete drug literature/product insert must accompany the product.
- 5 The following must be complied with specific for **inhalation anesthetics and cytotoxic injectable drugs.**
 - 5.1 **For inhalation anesthetics**
 - 5.1.1 Submit **certification from the bidder that inhalation bottle must be with safety sealed cap**, airtight and capable to dispense directly from bottle the possibility of ambient air coming into contact with agent to prevent contamination and spillage.
 - 5.1.2 Submit **certification from the bidder that product container or anesthetic agent is shatterproof and transparent for visual check of content.** Container material must ensure stability of the agent to prevent degradation, must not be easy to break.
 - 5.1.3 Winning bidder for Sevoflurane shall *provide at least thirty-five (35) vaporizers* on loan and in good working conditions until the validity of the contract.
 - 5.2 **For Cytotoxic Injectable Drugs**
 - 5.2.1 For cytotoxic injectable drugs, winning bidders are required to *provide Material Safety Data Sheet (MSDS) and to submit Drug Profile* to the Pharmacy Department per company under the first Purchase Order.
 - 5.2.2 Winning bidders for cytotoxic injectable drugs are required to **provide at least three (3) spill kits** per company under the first Purchase Order.
 - 5.2.3 For Paclitaxel, a special IV set must be provided per unit of the drug.
- 6 **New brands offered** shall be subject to further evaluation and shall require **the following:**
 - a. Validation of the submitted Certificate of Acceptance from at least three (3) major hospitals;
 - b. Justification from end-user/s to validate the acceptance of the good/s offered (to be facilitated by PGH-PSD).

Approved by:

Dean VICENTE Y. BELIZARIO, JR., MD, MTM&H
Chairperson

(Signature over Printed Name of President/Gen. Manager)

(Name & Address of Company)

Proj. Ref. No.: BAC4-21-033-A
End-User: Property and Supply Division
Project Name: SUPPLY & DELIVERY OF VARIOUS DRUGS AND MEDICINES (AMPULES/VIALS) FOR CY 2022 (FRAMEWORK AGREEMENT) - REBID

- 7 **For the supply and delivery of awarded drugs and medicines.**
- 7.1 Delivery of the goods is required as stated in the request of the end-user, commencing on the 3rd working day of notification through confirmed fax/email that the approved Call-off/ Notice to Supplier (NTS) is already available for pick up.
- 7.2 Delivery schedule (whichever is applicable):
- a) within seven (7) calendar days
 - b) as may be called for;
 - c) staggered delivery within three (3) months
- * 50% of the total quantity within seven (7) calendar days and 25% each for the succeeding months
- Note: The end-user has the right to adjust the quantity to be delivered depending on the actual need of the hospital*
- 7.3 Deliveries shall have **at least two (2) years expiration date.**
- 7.4 Delivery of goods **with product complaint shall be put on hold** until receipt of the final decision of the PGH management whether to proceed with the acceptance or to cancel/return the items.
- 7.5 Delivered **items found to be non-formulary at any given time shall be returned** to the company and a credit memo shall be issued.
- 7.6 Stocks delivered **are subject to random sampling for testing** as to quality and conformity to label. Testing fee at supplier's expense.
- 7.7 Stocks with lot #/batch different from the submitted Certificate of Analysis (COA) will be subjected to testing as to quality and conformity to label. Testing fee at supplier's expense.
- 7.8 All items that had been pulled out for various reasons, a credit memo shall be issued by the Contractor within one (1) month, otherwise, a debit memo shall be processed by UP Manila - PGH and the amount will be deducted from any amount due to Supplier.
- 7.9 It is understood that the Supplier is legally responsible to deliver all issued **CALL-OFF/s (Purchase Order) and failure to deliver the first Call-Off as scheduled shall mean automatic cancellation of the Call-Off and Notice to Execute Framework Agreement (NEFA).** Purchase from other source for whatever means shall be effected immediately to provide the requirements of the hospital. Penalty to the defaulting contractor shall be charged accordingly.
- 8 **Failure to comply with the submission of the required documents shall be ground for post-disqualification in accordance with RA 9184.**
- 9 Compliance with RA 9184 and other applicable laws.

Approved by:

Dean VICENTE Y. BELIZARIO, JR., MD, MTM&H
Chairperson

(Signature over Printed Name of President/Gen. Manager)

(Name & Address of Company)